Leerink Partnrs Upgrades Atyr PHARMA (NASDAQ:ATYR) to Strong-Buy

Atyr PHARMA (NASDAQ:ATYR) was upgraded by equities researchers at Leerink Partnrs to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other equities research analysts have also issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Leerink Partners assumed coverage on Atyr PHARMA in a research note on Tuesday. They issued an “outperform” rating and a $16.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Stock Up 12.1 %

Shares of Atyr PHARMA stock opened at $4.25 on Tuesday. The business’s 50 day simple moving average is $3.56 and its 200 day simple moving average is $2.85. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.29. The firm has a market cap of $356.75 million, a PE ratio of -4.52 and a beta of 1.10. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Alpine Global Management LLC bought a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $63,000. Woodline Partners LP bought a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $6,092,000. Squarepoint Ops LLC bought a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $96,000. Two Sigma Advisers LP bought a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $44,000. Finally, Two Sigma Investments LP bought a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $78,000. 61.72% of the stock is currently owned by institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.